Hypoparathyroidism


Also found in: Dictionary, Thesaurus, Medical, Wikipedia.
Related to Hypoparathyroidism: hyperparathyroidism, pseudohypoparathyroidism

hypoparathyroidism

[‚hī·pō‚par·ə′thī‚rȯi‚diz·əm]
(medicine)
Condition caused by insufficient functioning of the parathyroid gland.

Hypoparathyroidism

 

a condition caused by insufficient secretory activity of the parathyroid glands.

Hypoparathyroidism may arise after the removal of the parathyroid glands or after their injury during thyroid surgery. Hypoparathyroidism is accompanied by disorders in calcium metabolism, a disturbance in the assimilability of calcium in the gastrointestinal tract, lowered calcium content in the blood, and deformation of the teeth. The disturbance in calcium metabolism increases the excitability of the nervous system, and an inclination to spasms (tetany) appears. Spasms arise spontaneously or under the influence of provocative factors (for example, muscle strain, overheating, and contusions) in symmetrical groups of muscles (most often of the upper extremities, more rarely of the lower extremities, and even more rarely in the facial and other muscles). Hypoparathyroidism occurs in both latent and manifest forms. The latent form may not be outwardly evident and is manifested only in a fall in temperature of the extremities, paresthesia throughout the body, and spasms. Pregnancy, menstruation, mechanical and thermal irritation, poisoning, and infections can stimulate the transition from latent to manifest hypoparathyroidism. Treatment involves hormonal and vitamin therapy.

L. M. GOL’BER

References in periodicals archive ?
50%) in the methylene blue group suffered from temporary hypoparathyroidism, but none in the nano-carbon group did so, between which the difference was significant (t=4.
sup][5] summarized the presentations of 115 patients with HDR syndrome and demonstrated that 106/112 (95%) had hypoparathyroidism, 106/110 (96%) had various degrees of sensorineural deafness, and 74/115 (64%) had renal anomalies.
According to the company, Natpar (rhPTH[1-84]) is a recombinant human PTH and will be available as a 25, 50, 75 and 100 micrograms once-daily injection as adjunctive treatment for adult patients with chronic hypoparathyroidism who cannot be adequately controlled with standard therapy alone.
In chronic hypoparathyroidism, cognitive disorder, speech impediments, emotional lability, mental and sensation disorders, aches, irritability, cataracts, papillae oedema may be seen.
The report provides a snapshot of the global therapeutic landscape of Hypoparathyroidism
Serum calcium levels below 7mg/dl, phosphorus above 7mg/dl and low parathormone <12pg/dl is suggestive of hypoparathyroidism.
26 out of 100 patients had hypocalcemia associated with hyperphosphatemia, the cause of which was hypoparathyroidism most probably, however, confirmation is required by doing parathyroid harmone assay (PTH).
Natpara was not studied in patients with hypoparathyroidism caused by calcium-sensing receptor mutations or in patients with acute post-surgical hypoparathyroidism.
Hypoparathyroidism is a rare disease, affecting approximately 60,000 people in the United States.
Shire s Chief Executive Officer, Flemming Ornskov, MD, MPH, commented: The FDA s approval of NATPARA provides a new treatment option for patients with hypoparathyroidism a devastating rare disease with significant unmet need.
SBS is a potentially fatal gastrointestinal disorder that can leave patients dependent on intravenous feeding, and hypoparathyroidism is an endocrine disease caused by absent or damaged parathyroid glands.
Hypoparathyroidism is an uncommon disorder of calcium metabolism characterized by hypocalcemia and hyperphosphatemia, which are due to impaired parathyroid hormone (PTH) secretion or action (1).